IN BRIEF: RTW Biotech makes additional investment in Windward Bio

RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Invests USD1.7 million as part of portfolio company Windward Bio's USD165 million crossover financing. RTW Biotech says it first invested in the private, clinical-stage biotechnology company as part of its series A round back in January of last year. Notes that Windward Bio is focused on improving outcomes for people living with serious immunological diseases, with its lead programme WIN378 an antibody designed to treat asthma and chronic obstructive pulmonary disease.

"We are pleased to further support Windward Bio as it advances a differentiated portfolio of long‑acting immunology therapies with the potential to meaningfully improve outcomes for patients. WIN378 has the profile we look for in a best-in-class asset: a well-validated target, a clear durability advantage over existing treatments, and compelling clinical trial data. This financing round will position the Windward team well to set a new standard of care for patients with asthma and COPD," said Rod Wong, chief investment officer at RTW Investments.

Current stock price: USD2.14, down 1.8% on Friday morning in London

12-month change: up 77%

By Christopher Ward, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Rtw Biotech